Home > Insider Trading > Filing (0001209191-21-014684)

Filing Details

Accession Number:: 0001209191-21-014684
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-26 16:05:16
Reporting Period:: 2020-02-24

Accepted Time:: 2021-02-26 16:05:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1829802	Sensei Biotherapeutics Inc.	SNSE	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1797409	Cambrian Biopharma Inc	19 Morris Ave Brooklyn Navy Yard Building, 128 Brooklyn NY 11025		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-02-24	18,100	$16.84	4,750,894	No	4	P	Direct
Common Stock	Acquisiton	2021-02-24	900	$18.42	4,751,794	No	4	P	Direct
Common Stock	Acquisiton	2021-02-25	12,000	$15.79	4,763,794	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.43 to $17.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.
These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.95 to $18.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.59 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.